SG11201903145TA - Pharmaceutical complex formulation comprising amlodipine, losartan and chlorthalidone - Google Patents

Pharmaceutical complex formulation comprising amlodipine, losartan and chlorthalidone

Info

Publication number
SG11201903145TA
SG11201903145TA SG11201903145TA SG11201903145TA SG11201903145TA SG 11201903145T A SG11201903145T A SG 11201903145TA SG 11201903145T A SG11201903145T A SG 11201903145TA SG 11201903145T A SG11201903145T A SG 11201903145TA SG 11201903145T A SG11201903145T A SG 11201903145TA
Authority
SG
Singapore
Prior art keywords
gyeonggi
international
suwon
gil
losartan
Prior art date
Application number
SG11201903145TA
Inventor
Hyuk Jun Cho
Sol Ee Lim
Ho Taek Im
Yong Il Kim
Jae Hyun Park
Jong Soo Woo
Original Assignee
Hanmi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62076324&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201903145T(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hanmi Pharmaceutical Co Ltd filed Critical Hanmi Pharmaceutical Co Ltd
Publication of SG11201903145TA publication Critical patent/SG11201903145TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 1 MI 1411 0 11101 HOE HI 1 0 0111111E1U 1101 010 HIDE 1111 0E111 Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\" WO 2018/084627 A2 11 May 2018 (11.05.2018) WIPO I PCT — (51) (21) (22) (25) Filing Language: (26) (30) (71) Applicant: HANMI PHARM. CO (72) International Patent Classification: gil, Paldal-gu, Suwon-si, Gyeonggi-do 16488 (KR). IM, A61K 9/20 (2006.01) A61K 31/4178 (2006.01) Ho Taek; 117-1204, 27, Yonggu-daero 2394beon-gil, Gi- A61K 31/4422 (2006.01) A61K 31/404 (2006.01) heung-gu, Yongin-si, Gyeonggi-do 16909 (KR). KIM, International Application Number: Yong Il; 732-504, 52, Jeongja-ro 42beon-gil, Jangan-gu, PCT/KR2017/012396 Suwon-si, Gyeonggi-do 16325 (KR). PARK, Jae Hyun; 311-404, 460, Yeongtong-ro, Yeongtong-gu, Suwon-si, International Filing Date: Gyeonggi-do 16707 (KR). WOO, Jong Soo; 120-2303, 03 November 2017 (03.11.2017) 85, Hwasan-ro, Jangan-gu, Suwon-si, Gyeonggi-do 16420 (KR). English Publication Language: English (74) Agent: KIM, Sung Ho et al.; (WANNABE Patent & Law Firm), (Hongeun Bldg., Yeoksam-dong) 5F, 8, Teheran-ro Priority Data: 8-gil, Gangnam-gu, Seoul 06233 (KR). 10-2016-0145518 03 November 2016 (03.11.2016) KR (81) Designated States (unless otherwise indicated, for every ., LTD. [KR/KR]; 214, kind of national protection available): AE, AG, AL, AM, Muha-ro, Paltan-myeon, Hwaseong-si, Gyeonggi-do 18536 AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, (KR). CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, Inventors: CHO, Hyuk Jun; B-301, 46, Deogyeong-daero HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, 38 lbeon-gil, Jangan-gu, Suwon-si, Gyeonggi-do 16358 KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (KR). LIM, Sol Ee; #905, 17-9, Gwongwang-ro 196beon- MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, = © uniformity Title: PHARMACEUTICAL COMPLEX FORMULATION 126 4 CHLORTHALIDONE COMPRISING AMLODIPINE, LOSARTAN AND r -- = (54) = = = = = = = = = ei IN ei ,tD iv *t (57) 0 ----. done GO N agent for cardiovascular diseases, which has excellent quality and heat stability. C , 1 chlorthalidone 1 0 20 25 : The present invention relates to a pharmaceutical complex formulation including amlodipine, losartan, and chlorthali- as active ingredients. The pharmaceutical complex formulation of the present invention including amlodipine, losartan and as the active ingredients exhibits excellent dissolution characteristics of the active ingredients, and has high content and heat stability. Therefore, the complex formulation of the present invention can be used as a prophylactic or therapeutic [Continued on next page] WO 2018/084627 A2 IIII0 0 PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — without international search report and to be republished upon receipt of that report (Rule 48.2(g))
SG11201903145TA 2016-11-03 2017-11-03 Pharmaceutical complex formulation comprising amlodipine, losartan and chlorthalidone SG11201903145TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020160145518A KR101910902B1 (en) 2016-11-03 2016-11-03 Pharmaceutical complex formulation comprising amlodipine, losartan and chlorthalidone
PCT/KR2017/012396 WO2018084627A2 (en) 2016-11-03 2017-11-03 Pharmaceutical complex formulation comprising amlodipine, losartan and chlorthalidone

Publications (1)

Publication Number Publication Date
SG11201903145TA true SG11201903145TA (en) 2019-05-30

Family

ID=62076324

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201903145TA SG11201903145TA (en) 2016-11-03 2017-11-03 Pharmaceutical complex formulation comprising amlodipine, losartan and chlorthalidone

Country Status (12)

Country Link
KR (1) KR101910902B1 (en)
CO (1) CO2019004798A2 (en)
CR (1) CR20190264A (en)
DO (1) DOP2019000093A (en)
EA (1) EA201991107A1 (en)
EC (1) ECSP19038749A (en)
MX (1) MX2019005178A (en)
NI (1) NI201900046A (en)
PH (1) PH12019500778A1 (en)
SG (1) SG11201903145TA (en)
WO (1) WO2018084627A2 (en)
ZA (1) ZA201902718B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114705785A (en) * 2022-04-21 2022-07-05 厦门泓益检测有限公司 Method for detecting chlorophthalic acid in vegetable oil

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200143914A (en) * 2019-06-17 2020-12-28 주식회사유한양행 A pharmaceutical composition in a multi-layered tablet form comprising amlodipine or its salt and chlorthalidone its salt
KR20210074428A (en) 2019-12-11 2021-06-22 한미약품 주식회사 Pharmaceutical complex formulation comprising amlodipine, losartan and chlorthalidone
KR20210152943A (en) 2020-06-09 2021-12-16 한미약품 주식회사 Pharmaceutical combination preparation for the prevention or treatment of cardiovascular diseases including amlodipine, losartan and chlorthalidone in a single layer tablet
MX2022015607A (en) * 2020-06-09 2023-01-24 Hanmi Pharm Ind Co Ltd Complex pharmaceutical preparation, for preventing or treating cardiovascular disease, comprising amlodipine, losartan and chlorthalidone in single-layer tablet.
KR20220088362A (en) * 2020-12-18 2022-06-27 주식회사 대웅제약 New formulation comprising 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine for the oral administration

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1854454T3 (en) * 2002-01-16 2014-01-13 Boehringer Ingelheim Pharma Process for the preparation of amorphous telmisartan
JP2009513543A (en) * 2003-07-16 2009-04-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Chlorthalidone combination
KR100924236B1 (en) * 2009-06-23 2009-10-29 충남대학교산학협력단 Methods and apparatus for preparing ultra-fine particles with narrow particle size distribution
KR20150079373A (en) * 2013-12-30 2015-07-08 한미약품 주식회사 Composite formulation for oral administration comprising ezetimibe and rosuvastatin
KR101914930B1 (en) * 2015-03-31 2018-11-05 한미약품 주식회사 Pharmaceutical complex formulation comprising amlodipine, losartan and chlorthalidone

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114705785A (en) * 2022-04-21 2022-07-05 厦门泓益检测有限公司 Method for detecting chlorophthalic acid in vegetable oil

Also Published As

Publication number Publication date
WO2018084627A3 (en) 2018-07-26
WO2018084627A2 (en) 2018-05-11
CO2019004798A2 (en) 2019-05-21
CR20190264A (en) 2019-08-26
ZA201902718B (en) 2020-08-26
KR101910902B1 (en) 2018-10-24
NI201900046A (en) 2019-10-11
PH12019500778A1 (en) 2019-07-24
DOP2019000093A (en) 2019-09-30
MX2019005178A (en) 2019-08-05
ECSP19038749A (en) 2019-06-30
EA201991107A1 (en) 2019-09-30
KR20180049510A (en) 2018-05-11

Similar Documents

Publication Publication Date Title
SG11201903145TA (en) Pharmaceutical complex formulation comprising amlodipine, losartan and chlorthalidone
SG11201906395PA (en) Blockchain based data processing method and device
SG11201806863WA (en) Tetracyclic pyridone compounds as antivirals
SG11202000136YA (en) Preparation comprising vonoprazan
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201907023UA (en) Method of reducing neutropenia
SG11201808108XA (en) Synthesis of indazoles
SG11201907604UA (en) Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan
SG11201808686VA (en) Synthesis of indazoles
SG11201902531QA (en) Liquid pharmaceutical composition
SG11201805001UA (en) Method of treating influenza a
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201810429UA (en) Anti-cd19 antibody formulations
SG11201901394XA (en) Neisseria meningitidis vaccine
SG11201909615YA (en) Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same
SG11201805149XA (en) Compositions comprising 15-hepe and methods of using the same
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11201811708QA (en) Process for the preparation of microcapsules
SG11202000333UA (en) Bicyclic ketone compounds and methods of use thereof
SG11201903417PA (en) Ringing gel composition
SG11201806393QA (en) Use of gabaa receptor modulators for treatment of itch
SG11201804587QA (en) Isoindole compounds
SG11201901048VA (en) Pharmaceutical compositions and uses directed to lysosomal storage disorders
SG11201809882XA (en) Pharmaceutical combinations for treating cancer
SG11201804630SA (en) Preparation process for polypropylene with enhanced visual appearance